Courtagen Life Sciences, Inc. Releases epiSEEK™ World’s Most Comprehensive, Rapid, Next Generation Clinical Sequencing Test Targeting 327 Genes Associated With Epilepsy Phenotypes  
10/31/2012 7:34:42 AM

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc. today announced the expansion of their molecular diagnostics menu. The new genetic test, epiSEEK™, provides the complete sequence of 327 genes that have been reported in association with epilepsy phenotypes and nonspecific seizure disorders.